We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01593553
Recruitment Status : Unknown
Verified November 2017 by Professor Mårten Rosenqvist, Karolinska University Hospital.
Recruitment status was:  Active, not recruiting
First Posted : May 8, 2012
Last Update Posted : November 20, 2017
Sponsor:
Information provided by (Responsible Party):
Professor Mårten Rosenqvist, Karolinska University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine whether screening for atrial fibrillation by intermittent ECG recording and initiation of anticoagulation treatment among high risk individuals is cost-effective and can lower the incidence of stroke.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Stroke Other: ECG screening for atrial fibrillation using intermittent ECG recorder Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7173 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden.
Study Start Date : March 2012
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ECG screening
Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
 Other: ECG screening for atrial fibrillation using intermittent ECG recorder
ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
Other Name: Zenicor ECG recorder
No Intervention: Control group
Standard of care


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Ischaemic or haemorrhagic stroke, systemic embolism, major bleeding leading to hospitalization or death from any cause [ Time Frame: Five years. Interim analysis after 3 years. ]
    A composite endpoint of incidence of ischamemic and haemorrhagic stroke, incidence of systemic embolism, major bleeding requiring hospitalization and all cause mortality in the group randomized to screening compared to the control group


Secondary Outcome Measures :
  1. Ischaemic stroke [ Time Frame: Five years. Interim analysis after 3 years. ]
    Incidence of ischaemic stroke in the group randomized to screening compared to the control group

  2. Ischaemic stroke and systemic thromboembolism [ Time Frame: Five years. Interim analysis after 3 years. ]
    Incidence of ischaemic stroke and systemic thromboembolism in the group randomized to screening compared to the control group

  3. Ischaemic stroke and systemic thromboembolism [ Time Frame: Five years. Interim analysis after 3 years. ]
    Incidence of ischaemic stroke and systemic thromboembolism in the group participating in screening (as treated) compared to the control group

  4. Dementia [ Time Frame: Five years. Interim analysis after 3 years. ]
    Incidence of dementia in the group randomized to screening compared to the control group

  5. All cause mortality [ Time Frame: Five years. Interim analysis after 3 years. ]
    All cause mortality in the group randomized to screening compared to the control group

  6. Cardiovascular mortality [ Time Frame: Five years. Interim analysis after 3 years. ]
    Cardiovascular in the group randomized to screening compared to the control group

  7. Hospitalization due to cardiovascular disease [ Time Frame: Five years. Interim analysis after 3 years. ]
    Hospitalization due to cardiovascular disease in the group randomized to screening compared to the control group

  8. Ischaemic or haemorrhagic stroke, systemic embolism, major bleeding leading to hospitalization, hospitalization due to cardiovascular disease or death from any cause [ Time Frame: Five years. Interim analysis after 3 years. ]
    In the group randomized to screening compared to the control group

  9. Cost effectivity [ Time Frame: Five years ]
  10. Initiation and compliance to oral anticoagulation therapy [ Time Frame: Five years ]
    The National Prescription Drug's register will be used to study intiation and duration of oral anticoagulation therapy in a as-treated and per-protocol analysis in the screened population compared to the control group

  11. Detection of atrial fibrillation [ Time Frame: Five years ]
    Incidence of atrial fibrillation in the group randomized to screening compared to the control group

  12. Pulmonary embolism and deep vein thrombosis [ Time Frame: Five years ]
    Incidence of pulmonary embolism and deep vein thrombosis in the group randomized to screening compared to the control group


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   75 Years to 76 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men and women 75-76 years of age living in the region of Stockholm or Halland

Exclusion Criteria:

  • Not fulfilling the inclusion criteria
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01593553


Locations
Layout table for location information
Sweden
Karolinska Trial Alliance, KTA Prim
Stockholm, Sweden, 11361
Sponsors and Collaborators
Karolinska University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Professor Mårten Rosenqvist, Professor, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT01593553    
Other Study ID Numbers: Strokestop
First Posted: May 8, 2012    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: November 2017
Keywords provided by Professor Mårten Rosenqvist, Karolinska University Hospital:
Screening
Stroke prevention
Cost effectiveness
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes